ORAVIG- miconazole tablet
Galt Pharmaceuticals, LLC
ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults.
The recommended dosing schedule for ORAVIG is the application of one 50 mg buccal tablet to the upper gum region (canine fossa) once daily for 14 consecutive days.
ORAVIG should be applied in the morning, after brushing the teeth. The tablet should be applied with dry hands. The rounded side surface of the tablet should be placed against the upper gum just above the incisor tooth (canine fossa) and held in place with slight pressure over the upper lip for 30 seconds to ensure adhesion. The tablet is round on one side for comfort, but either side of the tablet can be applied to the gum.
Once applied, ORAVIG stays in position and gradually dissolves. [ See Clinical Pharmacology (12.3)] Subsequent applications of ORAVIG should be made to alternate sides of the mouth. Before applying the next tablet, the patient should clear away any remaining tablet material. In addition,
- ORAVIG should not be crushed, chewed or swallowed.
- Food and drink can be taken normally when ORAVIG is in place but chewing gum should be avoided.
- If ORAVIG does not adhere or falls off within the first 6 hours, the same tablet should be repositioned immediately. If the tablet still does not adhere, a new tablet should be placed.
- If ORAVIG is swallowed within the first 6 hours, the patient should drink a glass of water and a new tablet should be applied only once.
- If ORAVIG falls off or is swallowed after it was in place for 6 hours or more, a new tablet should not be applied until the next regularly scheduled dose. [ see Patient Counseling Information (17)].
ORAVIG is a buccal tablet containing 50 mg of miconazole. ORAVIG tablets are round, off-white tablets, with a rounded side and a flat side. The tablets are marked with an “L” on the flat side.
ORAVIG is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to miconazole, milk protein concentrate, or any other component of the product.
Allergic reactions, including anaphylactic reactions and hypersensitivity, have been reported with the administration of miconazole products, including ORAVIG. Discontinue ORAVIG immediately at the first sign of hypersensitivity.
There is no information regarding cross-hypersensitivity between miconazole and other azole antifungal agents. Monitor patients with a history of hypersensitivity to azoles.
The following serious adverse drug reactions are discussed in detail in other sections of labeling:
- Hypersensitivity reactions [see Warnings and Precautions (5.1)]
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The overall safety of ORAVIG was assessed in 480 adult subjects: 315 HIV-infected subjects, 147 subjects with head and neck cancer, and 18 healthy subjects.
HIV Infected Patients
Two trials were conducted in immunocompromised HIV-infected patients: one randomized, double-blind, double-dummy, active-controlled design (N = 290 ORAVIG, 287 control) and one non-comparative trial (N = 25).
In the randomized, double blind trial (Study 1), 290 HIV infected subjects used ORAVIG once daily for 14 days, and 287 subjects used 10 mg clotrimazole troches five times daily for 14 days. Adverse reactions occurring in ≥ 2% of patients in either treatment are presented in Table 1.
Table 1 Adverse Reactions (Treatment-Emergent) Occurring in ≥ 2% of HIV-Infected Patients in the Controlled Clinical Trial
|Adverse Reaction (MedDRA v 9.1 System Organ Class and Preferred Term)||ORAVIG N = 290 (%)||Clotrimazole troches N = 287 (%)|
|Patients with any adverse reaction during the study||158 (54.5)||146 (50.9)|
|Gastrointestinal disorders Diarrhea Nausea Vomiting Dry mouth Abdominal pain upper||25.9 9.0 6.6 3.8 2.8 1.7||23.7 8.0 7.7 3.1 1.7 2.8|
|Infections and infestations Upper respiratory infection Gastroenteritis||15.9 2.1 1.4||17.1 2.4 2.8|
|Nervous system disorders Headache Ageusia||13.1 7.6 2.4||8.4 6.6 0.3|
|Blood and lymphatic disorders Anemia Lymphopenia Neutropenia||6.9 2.8 1.7 0.7||8.4 1.7 2.1 2.1|
|General disorders and administration site conditions Fatigue Pain||6.6 2.8 1.0||8.0 2.1 2.8|
|Respiratory/thoracic Cough Pharyngeal pain||5.2 2.8 0.7||7.7 1.7 2.4|
|Investigations Increased GGT||5.5 1.0||6.3 2.8|
Overall local adverse reactions, including oral discomfort, oral burning, oral pain, gingival pain, gingival swelling, gingival pruritis, tongue ulceration, mouth ulceration, glossodynia, dry mouth, application site pain or discomfort, toothache, loss of taste, and altered taste, were reported by 35 (12.1%) patients who received miconazole buccal tablet compared to 27 (9.4%) patients who received clotrimazole troches.
Head and Neck Cancer Patients
In the randomized, open-label comparative trial of oropharyngeal candidiasis in patients with head and neck cancer who had received radiation therapy (Study 2), 147 patients used ORAVIG once daily for 14 days and 147 patients used 125 mg of miconazole oral gel four times daily for 14 days. Adverse reactions occurring in ≥2% of patients in either arm are listed in Table 2.
Table 2: Adverse Reactions (Treatment-Emergent) Occurring in ≥ 2% of Patients with Head and Neck Cancer who had Received Radiation Therapy (Controlled Clinical Trial)
|Adverse Reaction (MedDRA v 9.1 System Organ Class and Preferred Term)||ORAVIG N = 147 (%)||Miconazole gel N = 147 (%)|
|Patients with at least one adverse reaction||30 (20.4)||32 (21.8)|
|Gastrointestinal disorders Abdominal pain, upper Oral discomfort Nausea Vomiting Glossodynia||8.8 1.4 2.7 0.7 0.7 0||13.6 2.0 2.7 2.7 2.0 2.0|
|Nervous system disorders Dysgeusia||5.4 4.1||1.4 0|
|Skin and subcutaneous Pruritus||3.4 2.0||0.7 0.7|
Overall local adverse reactions, including oral discomfort, oral pain, dry mouth, glossodynia, loss of taste, altered taste, tongue ulceration, mouth ulceration, tooth disorder, and application site discomfort or pain, were experienced by 14 (9.5%) patients who used ORAVIG compared to 16 (10.9%) patients who used miconazole gel.
Overall ORAVIG Safety Experience In Patients and Healthy Subjects
Adverse reactions reported in the overall safety database of 480 subjects who received miconazole buccal tablet is listed in Table 3.
Table 3 Adverse Reactions Reported in ≥ 2% of Patients and Healthy Subjects who Received ORAVIG in Clinical Trials
|Adverse reaction (MedDRA v 9.1 System Organ Class and Preferred Term)||ORAVIG N = 480 (%)|
|Patients with at least one AE||209 (43.5)|
|Gastrointestinal disorders Diarrhea Nausea Abdominal pain upper Vomiting||20.6 6.0 4.6 2.5 2.5|
|Infections and infestations||11.9|
|Nervous system disorders Headache Dysgeusia||10.6 5.0 2.9|
Discontinuation of ORAVIG due to adverse drug reactions occurred in 0.6% overall.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.